Pembrolizumab (P) or P plus chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.

D Rischin; KJ Harrington; Richard Greil; D Soulieres; M Tahara; G Castro; A Psyrri; N Baste; PC Neupane; A Bratland; T Fuereder; BGM Hughes; R Mesia; N Ngamphaiboon; T Rordorf; WZW Ishak; JX Lin; B Gumuscu; RF Swaby; B Burtness

Pembrolizumab (P) or P plus chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.

D Rischin, KJ Harrington, Richard Greil, D Soulieres, M Tahara, G Castro, A Psyrri, N Baste, PC Neupane, A Bratland, T Fuereder, BGM Hughes, R Mesia, N Ngamphaiboon, T Rordorf, WZW Ishak, JX Lin, B Gumuscu, RF Swaby, B Burtness

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

3 Citations (Web of Science)

Original language	English
Journal	JOURNAL OF CLINICAL ONCOLOGY
Volume	38
Issue number	15
Publication status	Published - 2020

Cite this

Rischin, D., Harrington, KJ., Greil, R., Soulieres, D., Tahara, M., Castro, G., Psyrri, A., Baste, N., Neupane, PC., Bratland, A., Fuereder, T., Hughes, BGM., Mesia, R., Ngamphaiboon, N., Rordorf, T., Ishak, WZW., Lin, JX., Gumuscu, B., Swaby, RF., & Burtness, B. (2020). Pembrolizumab (P) or P plus chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state. JOURNAL OF CLINICAL ONCOLOGY , 38(15).

Rischin, D ; Harrington, KJ ; Greil, Richard et al. / Pembrolizumab (P) or P plus chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state. In: JOURNAL OF CLINICAL ONCOLOGY 2020 ; Vol. 38, No. 15.

@article{a7edb98843b744eb94077ad2d21c928c,

title = "Pembrolizumab (P) or P plus chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.",

author = "D Rischin and KJ Harrington and Richard Greil and D Soulieres and M Tahara and G Castro and A Psyrri and N Baste and PC Neupane and A Bratland and T Fuereder and BGM Hughes and R Mesia and N Ngamphaiboon and T Rordorf and WZW Ishak and JX Lin and B Gumuscu and RF Swaby and B Burtness",

year = "2020",

language = "English",

volume = "38",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

number = "15",

}

Rischin, D, Harrington, KJ, Greil, R, Soulieres, D, Tahara, M, Castro, G, Psyrri, A, Baste, N, Neupane, PC, Bratland, A, Fuereder, T, Hughes, BGM, Mesia, R, Ngamphaiboon, N, Rordorf, T, Ishak, WZW, Lin, JX, Gumuscu, B, Swaby, RF & Burtness, B 2020, 'Pembrolizumab (P) or P plus chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.', JOURNAL OF CLINICAL ONCOLOGY , vol. 38, no. 15.

Pembrolizumab (P) or P plus chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state. / Rischin, D; Harrington, KJ; Greil, Richard et al.
In: JOURNAL OF CLINICAL ONCOLOGY , Vol. 38, No. 15, 2020.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Pembrolizumab (P) or P plus chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.

AU - Rischin, D

AU - Harrington, KJ

AU - Greil, Richard

AU - Soulieres, D

AU - Tahara, M

AU - Castro, G

AU - Psyrri, A

AU - Baste, N

AU - Neupane, PC

AU - Bratland, A

AU - Fuereder, T

AU - Hughes, BGM

AU - Mesia, R

AU - Ngamphaiboon, N

AU - Rordorf, T

AU - Ishak, WZW

AU - Lin, JX

AU - Gumuscu, B

AU - Swaby, RF

AU - Burtness, B

PY - 2020

Y1 - 2020

M3 - Abstract (Journal)

SN - 0732-183X

VL - 38

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 15

ER -

Rischin D, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro G et al. Pembrolizumab (P) or P plus chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state. JOURNAL OF CLINICAL ONCOLOGY . 2020;38(15).